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The excessive and improper use of antibiotics has led to an increasing incidence of bacterial resistance. In Europe the yearly number
of infections caused bymultidrug resistant bacteria is more than 400.000, each year resulting in 25.000 attributable deaths. Few new
antibiotics are in the pipeline of the pharmaceutical industry. Early in the 20th century, bacteriophages were described as entities
that can control bacterial populations. Although bacteriophage therapy was developed and practiced in Europe and the former
Soviet republics, the use of bacteriophages in clinical setting was neglected inWestern Europe since the introduction of traditional
antibiotics. Given the worldwide antibiotic crisis there is now a growing interest in making bacteriophage therapy available for
use in modern western medicine. Despite the growing interest, access to bacteriophage therapy remains highly problematic. In
this paper, we argue that the current state of affairs is morally unacceptable and that all stakeholders (pharmaceutical industry,
competent authorities, lawmakers, regulators, and politicians) have the moral duty and the shared responsibility towards making
bacteriophage therapy urgently available for all patients in need.
1. Introduction
1.1. Factual (Nonnormative)Observations concerning Bacterio-
phageTherapy. The excessive and improper use of antibiotics
has led to an increasing incidence of bacterial resistance
and a significant threat to human health [1, 2]. Yearly, more
than 400.000 people are infected by multidrug resistant
bacterial strains, often called “superbugs” [3]. Superbugs
have a considerable economic impact: extra hospital costs
and related productivity losses amount to more than 1.5
billion Euros per year within the European Union (EU).
In the United States (US), infections with multidrug resistant
bacteria cause 20 billion US$ in additional health care costs
and 35 billion US$ societal costs annually [4].
At the same time, it is becoming more and more difficult
and expensive to develop new antibiotics as an adequate
response to the phenomenon of multidrug resistance. Actu-
ally, very few new antibiotics are in the pipeline of the
pharmaceutical industry at the moment [5].
Early in the 20th century, bacteriophages were described
as entities that can control bacterial populations. Bacterio-
phages (or “phages”) are viruses that infect and replicate
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within specific bacteria without harming others. Although
bacteriophage therapy (hereafter BPT) was developed and
practiced in Europe and the former Soviet republics, the
western world abandoned the use. This was mainly because
at that time (1930s) there was a lack of knowledge of what a
bacteriophage really was (a virus) as well as the discovery of
antibiotics. These molecules are well-characterized chemical
substances, relatively easy to produce in a well-controlled
fashion, initiating the golden age of antibiotics, the so called
“miracle drugs” [6].
Given the worldwide antibiotic crisis, the existing and
continued experiences build up in Eastern Europe and the
former Soviet Republics combined with recent encouraging
animal and human study results; there is a growing interest
for BPT in modern medicine and the agrobioindustry, a
recognized potential reservoir for antibiotic resistant germs
[1, 3, 7–10].
Despite this growing interest, introducing BPT in the
western medical world remains highly problematic as a con-
sequence of four main obstacles. First, historical clinical data
about the safety and effectiveness of BPT are not considered
proven and validated by European regulators. Second, given
the substantial costs and investment in the development
and marketing of conventional medicinal products by the
pharmaceutical industry, there is in our actual pharmacoeco-
nomic model an imperative demand for a strong intellectual
property (IP) protection. For now, such protection is rather
fragile for natural lytic phages.Third, an efficient and effective
BPT-concept needs to be flexible and tailored to the patient
[11, 12]. That requirement is not compatible with the usual
timeframes (years) for the development and the marketing
of conventional medicinal products [11, 12]. Rather, the
regulatory framework for medicinal product development,
as present in most countries, calls for drugs to have a
fixed chemical composition. Bacteriophages challenge this
definition by being mutable. Last (fourth obstacle), uncer-
tainty exists about the potential negative coevolutionary
consequences of unlimited use of BPT [13]. In view of these
obstacles, access to BPT for patients in need remains highly
problematic as discussed earlier [12, 14].
Recently, Henein emphasized that so far no bioethical
bacteriophage therapy debate has been published. He gave
the most recent E. coli 0104 outbreak as an example [15].
Indeed in 2011, an emerging strain ofO104:H4Escherichia coli
caused a serious outbreak of food borne haemolytic uremic
syndrome and bloody diarrhoea in Germany. Antibiotics
were of questionable use and 54 deaths occurred, beside
tens of clinical cases with lasting sequels [16, 17]. Several
bacteriophage research groups had in their collection isolated
candidate therapeutic bacteriophages that efficiently lyse the
E. coli O104:H4 outbreak strain [18–20]. The public health
sector never asked for these phages during the outbreak and
none of the scientific papers published during the outbreak
mentioned BPT as a potential treatment. Nestle´ Research
Centre even offered their phage isolate to the German public
health sector during the epidemic, but the proposal was
apparently not addressed [20].
Międzybrodzki et al. [21] addressed briefly the ethical
aspects of bacterial drug resistance and phage therapy.
The authors also highlighted the appeals for decisive changes
in the policies governing the development of antimicrobials.
Bacteriophages should be considered as a public good and the
government should be responsible for their development and
production. Thus, the development and introduction of new
antimicrobials should not only be regulated by market forces
[21].
The main purpose of this paper is not so much to fleece
out these four main obstacles, nor to determine how an
adequate regulatory framework for BPTmight look like.This
has already been done in other publications [11, 12, 14, 22].
We here argue why there exists a moral need or duty to
develop such a regulatory framework. The different actors
in the field, mainly the industrial partners, politicians and
regulators as well as consumers, urgently need to take up
their responsibility in order to guarantee BPT accessibility
for patients in need. What is more, when the costs of phage
therapy and antibiotic therapy were compared, phages were
approximately 50% cheaper than antibiotics. This means that
a wider application of phage therapy could lead to substantial
savings in healthcare costs and make antibacterial therapy
accessible to those who otherwise cannot afford treatment
[23].
1.2. Normative-Ethical Considerations concerning BPT. Given
the above nonnormative specifications of BPT, the basic
moral problem associated with BPT can be formulated as
follows. BPT, when used in a flexible (tailor-made, locally
developed) and sustainable manner, has the potential of
saving thousands of lives every year [11, 24]. However, due
to the above-mentioned obstacles, access to that therapy
remains highly problematic in thewesternworld.How canwe
argue from a moral point of view that this situation is simply
unacceptable?
Central to this moral problem are the preservation and
restoration of the health and well-being of the patient. Two
basic underlying moral principles are relevant in this patient-
centred approach and will be further investigated in this
paper. The first is the principle of nonmaleficence, which
implies the obligation not to inflict harm on another. This
principle is designed to protect the patient. The second
principle is the principle of beneficence, which implies the
obligation to prevent or to remove harm or the obligation to
promote good [25].
2. Bacteriophage Therapy: An Ethically
Justified Medical Therapy?
The fact that efficacy of BPT has not yet been proven accord-
ing to European regulatory standards is one of the obstacles
that clearly suggests the moral relevance to investigate the
principle of nonmaleficence in the context of BPT. Indeed, a
patient has a right not to be subjected to a medical treatment
or therapy that has not yet been rigorously tested for its
effectiveness and possible health risks (as is BPT). The moral
duty, however, not to subject a patient to a not yet approved
therapy is not an absolute, but a prima facie duty. This means
that under well-defined, specific circumstances this duty not
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Table 1: Six criteria for a therapy to be labelled as an EJMT.
It is morally permissible to set aside the prima facie duty not to impose a risk of harm if and only if
(i) there is a just cause;
(ii) those who want to put aside the duty not to impose a risk of harm have good intentions;
(iii) there is a reasonable chance that the just cause will be realized;
(iv) the harm prevented will outweigh the risk of harm imposed;
(v) the just cause cannot be obtained with at least the same probability of success but without imposing a risk of harm;
(vi) those who decide on putting aside the duty not to impose a risk of harm constitute a legitimate authority.
to subject someone to a not yet approved therapy can be set
aside [26]. At this point in the argument, it is appropriate
to introduce the notion of an “Ethically Justified Medical
Therapy” (EJMT). This is a medical therapy that has not yet
obtained an official approval for its health effectiveness (at
least not according to western standards), and/or for which
some doubts remain concerning possible health risks, but the
use of which seems to bemorally acceptable given the specific
circumstances of the case at hand. For such a therapy to be
labelled as an EJMT, six criteria need to be met (Table 1) [27].
First of all, there has to be a just cause or a very good
reason for subjecting a patient to a possibly hazardous
medical therapy and/or a therapy the effectiveness of which
has not yet been demonstrated in a rigorous manner. The
moral weight of whatever it is we want to achieve with this
therapy has to be sufficiently important. In the case of BPT-
therapy we might think of a patient whose life or limb is
threatened by a serious bacteriological infection. Saving that
patient’s limb or threatened life, for instance, constitutes such
a good reason beyond any doubt.
Secondly, we need to make sure that all the moral agents
involved are motivated by ethically proper intentions. In a
clinician-patient relationship, the medical practitioner ought
to have the intention to help the patient in need, although
other interests (e.g., hospital-related) may play a certain
role as well. Therefore, if indeed a patient’s health is at
stake (a good reason), then our intention for using the yet
unapproved therapy has to be about improving the patient’s
health condition and not about commercial, research, or cost-
reducing benefits.
Next, there needs to be a reasonable chance that the use of
the therapy in a particular case will have the desired result. In
case of BPT, based on preliminary examinations and testing
by experienced specialists, multiple case studies reporting
success were published [28–30].
Efficacy of bacteriophage therapy has not yet been proven
according to European regulators, but anyway the concept
of reasonable chance does not imply real proof of such
efficacy.What is more, there must be a good prospect that the
probable health benefits will outweigh the risks of subjecting
the patient to the therapy (proportionality). It is important in
this respect to try to avoid as much as possible undesired side
effects related to BPT [31–33].
Another criterion is that the unapproved therapy needs
to be a last resort. All existing treatments must have been
tried with little or no success. BPT might for instance be
considered as such a last resort when marketed antibiotics
are no longer effective. In reality, in particular circumstances
of multidrug resistance, BPT offers today a reasonable and
feasible alternative or complimentary treatment approach to
save such patients. Indeed it has been shown that BPT and
traditional antibiotic therapy can create a synergic beneficial
effect [34, 35].
Medical practitioners’ assessment in these circumstances
is crucial. It needs to be stressed that in clear cases of
antibiotic resistance, BPT most likely constitutes the first
and not just the last resort. Indeed, the last resort principle
only demands that we consider reasonable alternatives, since
hopeless situations due to lack of adequate alternatives need
to be avoided as much as possible according to international
and national legislations and declarations. In Belgium, the
compassionate use regime provides such a “last resort”
mechanism, whereby a medical practitioner may apply an
unapproved product provided marketing authorization is
applied for or clinical trials are ongoing. At the international
level, Article 37 of the Declaration of Helsinki states the
following: “In the treatment of an individual patient, where
proven interventions do not exist or other known interventions
have been ineffective, the physician, after seeking expert advice,
with informed consent from the patient or a legally authorized
representative, may use an unproven intervention if in the
physician’s judgement it offers hope of saving life, re-establishing
health or alleviating suffering. This intervention should subse-
quently be made the object of research, designed to evaluate
its safety and efficacy. In all cases, new information must
be recorded and, where appropriate, made publicly available”
[36].Note however, that theDeclaration ofHelsinki, although
at the international medical community level is well accepted
as a basic document, is not a national binding law, meaning
that it has no national juridical value and as such could put
the practitioner in a position of juridical vulnerability as
experienced in France (personal communications, M.D. A.
Dublanchet and Court Lawyer B. Papin).
Finally, a decision to subject a patient to a not yet
approved therapy needs to be made in respect with the
patient’s right to autonomy (legitimate authority) [26]. How-
ever, it should be noted that a patient’s consent to be
subjected to a not yet approved treatment is not a sufficient
condition to go ahead with the therapy. The other above-
mentioned criteria need to be respected as well. Within this
context, we need to determine whether a patient’s (or its legal
representative) consent constitutes a necessary condition.
Although these six criteria were originally developed
within another context, namely, that of the just war theory
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(JWT), it seems that these criteria can also be of valuable
use in the ethical discussion on BPT [37]. This is because
the underlying ethical argument is very similar. The JWT
starts from the supposition that war is a moral evil, and
that because of this we have an obligation to avoid war as
much as possible. Notice here again that the obligation not
to wage war is not an absolute, but a prima facie duty. In
specific circumstances (determined by the above criteria)
war can be a morally acceptable option (for instance in
case of self-defense or humanitarian intervention). A very
similar moral mechanism is at work in our discussion about
BPT. Subjecting a patient to a not yet approved therapy
is morally wrong, but sometimes, in specific (exceptional)
circumstances (determined by the six criteria), it can be
a morally acceptable option to subject a patient to such
unapproved therapy, and not just amorally excusable option.
Whether or not BPT is an EJMT needs to be checked on
a case-by-case basis. Numerous types of bacterial infections
exist. Any manner to combat such infection needs to be
considered separately. In fact, medical ethical committees
provide also case-by-case reasoning while evaluating propos-
als for treatment.
We would like to conclude the first part of our argument
by saying that the six criteria we used to evaluate BPT’s moral
permissibility form the ethical basis for some kind of pre-
cautionary regulatory framework. Until it can be adequately
shown that BPT can live up to western health care standards,
there will be a constant need to justify the use of BPT on a
case-by-case basis.Moreover, given the specific nature of BPT
(its interactive and ever-evolving character) and the need
to focus on tailor-made solutions, it will be difficult, if not
impossible, to claim once and for all (as it is probably the case
for traditional “static” chemicalmedicinal products) that BPT
is effective and safe.This would also imply that any regulatory
framework designed to assure the safety and effectiveness of
flexible and sustainable BPT will never completely lose its
precautionary character.
3. Towards a Moral Duty to Invest in
the Development of Bacteriophage Therapy
3.1. Do Pharmaceutical Companies Have a Duty to Care?
Demonstrating that BPT constitutes an EJMT in a sufficient
number of cases is of course but a first part of our moral
argument. Showing that in a specific case BPT is an EJMT
makes its use morally permissible in that specific case. But
showing moral permissibility for BPT is only a necessary
condition for our purpose, which is demonstrating that it is
simply morally unacceptable to obstruct (or, at least, to not
sufficiently facilitate) the accessibility to BPT. We also need
to show that somehow there exists a moral duty to take the
necessary steps in order to make flexible and sustainable BPT
available in a more organized fashion.
Pharmaceutical companies are the primary actors in
the business of developing new and improved medicinal
products and therapies. Hospitals do not have the financial
capacity and resources to fully develop bacteriophage-based
products according to the current pharmaceutical medicinal
product guidelines. Although our initial focus will be on
pharmaceutical companies, this does not mean that other
actors (like public authorities) are absolutely absolved of all
responsibility in this respect. We will come back to this
specific issue later on in this paper.
In our patient-centred approach, we perceived that the
principle of nonmaleficence provides a so-called prima facie
moral protection for the patient against therapies and treat-
ments that have not yet proven their health effectiveness
and/or for which some doubts remain concerning their
possible health risks. In trying to establish a moral duty to
contribute to the development of lifesaving therapies, such as
BPT [28, 30, 38], it is suitable to turn to the other basic moral
principle in bioethics, that of beneficence.
Despite the fact that it is not in the interest of the
classic pharmaceutical industry, organized in accordance
with the actual pharmacoeconomic environment, to invest
in sustainable BPT (see the above mentioned obstacles), the
beneficence-principle seems to provide a sufficient moral
basis for arguing that the pharmaceutical industry has a duty
to do so anyway.
In the 1970s, most supporters of market economy
embraced Friedman’s view that the social responsibility of
business is to increase its profits, not to relax the conditions of
profit-maximization on behalf of thewider interests of society
[39]. But, is this acceptable when it comes to healthcare?
Surely, companies involved in the healthcare industry should
live up to their responsibilities towards the public interest,
not only towards their shareholders. To quote Blasszauer:
“medicine is a moral enterprise whether it is practiced in
the system of slavery or market economy” [40]. Defenders of
Friedman’s thesis claim that for executives to use company
resources to advance social goals, it would be for them to
usurp the political function. In this context it might thus be
up to the political world to demand healthcare companies to
defy the laws of economics and fulfil social duties [12, 41].
One of the reasons why the above conclusion is not that
straightforward has to do with the specific nature of the
beneficence-principle. Indeed this basic principle is especially
morally relevant within the relation between the health care
professional and his patient. Because of his specific role, it
can be said that the health care professional has the moral
obligation to undertake all the necessary and reasonable
measures to improve his patient’s health condition (or to
prevent his patient’s health fromdeteriorating).The relational
context between a patient and the pharmaceutical industry
is of course very different from the one between the health
care professional and his patient. It is no longer a relation
of care, compassion, and beneficence, but a relation of an
economic or a commercial kind. The industry’s role is to
develop, produce, and sell medicinal products, whereas the
role of the patient is that of a consumer. This does not
mean that the pharmaceutical industry has absolutely no
obligations whatsoever towards its patient-consumers. The
industry has the obligation to take all the necessary and
reasonablemeasures to ensure the effectiveness and the safety
of the medicinal products it decides to develop, produce, and
sell [42]. Within that same commercial relation (“patient-
consumer/pharmaceutical industry”) it is very hard, as far
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as we can tell, to justify the imposition of an additional
requirement on the pharmaceutical industry to invest in the
development and production of medicinal products that are
of a lifesaving importance to some patients, but that are rather
uninteresting from a pure commercial point of view as is the
case for flexible and sustainable BPT that has been shown
lifesaving in specific individual cases [28, 30, 38]. Here we
need to look for another way to morally justify an obligation
to make available for as many patients as possible medicinal
products or therapies for which there does not seem to exist
a sufficient commercial incentive to start a development and
production process.
3.2. Do Pharmaceutical Companies Have a Social Responsibil-
ity to Invest in BPT inOrder to PromoteOverall SocialWelfare?
Perhaps a more promising line of argument is of a utilitarian
kind. One might quite convincingly argue that economic
actors in our society, like private businesses and companies,
do not only have specific client-related obligations, but also
a somewhat broader social responsibility to promote overall
well-being in society. If we agree that this is the case (that
there exists such a utilitarian-based responsibility), then it
still remains to be seen of course whether the moral require-
ment to promote novel antimicrobial approaches like BPT
can indeed be based on such a notion of social responsibility.
To verify this, we need to explore two separate questions.
The first question goes as follows: to what extent may we
assume that the promotion of BPT (eventually in combina-
tion with existing therapies) constitutes indeed the course of
action that, compared to other possible alternatives, will lead
to better results in confronting the health challenges related
to an increasing antibiotic resistance problem in bacteria
(hereafter the resistance problem)? Proving that BPT is the
best option in tackling this specific health problem from a
utilitarian point of view is essentially a technical matter that
requires further thorough knowledge in microbiology and
in health care economics. In other publications it has been
shown that this may be the case [7, 43, 44].
Establishing with a reasonable degree of certainty that
BPT is indeed a good option in confronting the resistance
problem from a utilitarian point of view constitutes, however,
a necessary, but not a sufficient condition for our purpose to
demonstrate that there is such a thing as a moral requirement
to promote BPT. A part of our common-sense morality
clearly states that promoting the best overall result does not
automatically generate a moral requirement to do so. We
can illustrate this with an example. Suppose that ten people
are on the verge of losing their lives (that they are about
to drown). Suppose also that person A could save all of
them if he wanted to. The only trouble is that person A can
only do so with a considerable risk to himself. Although,
saving the ten lives (even with the risk of losing his own
life in the process) is the best option from a utilitarian
point of view; there is a general agreement within common-
sense morality that person A is under no moral obligation
to do so. In this specific example person A is allowed to
favour his own life, even if sacrificing it in order to save the
ten others would be preferable from a utilitarian viewpoint.
In the theory of normative ethics, common-sense moral-
ity contains so-called agent-favouring options (or agent-
favouring prerogatives) [45]. These are moral principles that
protect an agent from the obligation to always promote the
overall good. The key word here is “always”.
Indeed, in some cases the promotion of the overall good
does create a moral requirement to do so. For instance:
if person A could save the lives of those ten people with
practically no risk for himself, he can no longer avoid the
obligation to do so. In order to understand the mechanism
of the agent-favouring options better, it is essential to take
into account two factors: the (probable) cost to the agent, and
the (probable) amount of overall good or well-being that is at
stake. If the amount of good at stake outweighs the cost to the
agent (who has no risk to lose his life), then the requirement
to promote the overall good can no longer be blocked by
the agent-favouring option. This seems to suggest that the
option protecting amoral agent’s self-interest is characterized
by some kind of threshold, the level of which is determined
by the cost the moral agent will have to pay when he decides
to serve the overall good. Once the amount of good or well-
being at stake crosses that threshold, the creation of a moral
requirement to bring about this amount of good canno longer
be blocked by the agent-favouring option. A general rule
seems to be then: the higher the cost to the agent, the higher
the threshold, the stronger the agent-favouring option, and
the lesser the probability that the agent will be subjected to
the obligation to promote the overall good. It should be clear,
however, that whenever the interests of an agent are protected
by such an agent-favouring option, he or she is still at liberty
to promote the overall good. If, for instance, person A is a
heroic kind of a person and he will not hesitate to save those
ten people, even if this means sacrificing his own life. It is
obvious that such an act will not be morally condemned. Far
from it: such an act will typically be praised and admired. But
again, it is not an obligatory act, but rather a supererogatory
act inspired by idealism [46].
Let us assume for the sake of argument that such agent-
favouring options are indeed a part of our common-sense
morality. This being the case, it might very well be that the
economic and commercial interests of the pharmaceutical
industry are going to be protected by such options. Even
if it would appear that promoting BPT is indeed the best
choice in tackling the resistance problem, pharmaceutical
enterprises cannot be morally obligated to sacrifice their
own commercial interests in order to give priority to the
development of BPT. It is possible, however, that some
pharmaceutical companies could decide to go ahead anyway
with the development of BPT. But, again, such a decision
would constitute a supererogatory act, not a mandatory act.
We now come to our second question: is it reasonable to
assume that there exists such an agent-favouring option that
protects the private interests of the pharmaceutical industry
and thereby blocks the creation of a moral requirement
to promote BPT? Answering this question requires a more
profound cost/benefit analysis. In case of pharmaceutical
companies’ investments in bacteriophage product develop-
ment, costs are considerable since all regulatory processes
need to be conducted [20]. Assuming that (a) cost-based
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option(s) protecting the interests of a moral agent is (are)
indeed a part or our common-sense morality and (b) the
development of BPT will definitely entail a commercial costs
to a pharmaceutical company (resources that will be invested
in this kind of research and development can no longer be
used to develop more lucrative products); it is also fair to
assume that pharmaceutical companies will try to protect
their private interests by appealing to such agent-favouring
option and pretend that there is no such thing as a duty to
promote BPT. Whether or not the pharmaceutical industry
is justified in hiding behind such agent-favouring option will
depend on two factors: what is the moral force of that option
and will it be strong enough to block a moral requirement
to promote BPT? At this point in the argument we will need
to evaluate the importance of the cost to the pharmaceutical
industry. This will indeed give us some idea of the moral
force of the agent-favouring option (the higher the cost, the
stronger the option). Today, any organization, pharmaceuti-
cal company, or any nonprofit actor like a hospital, willing to
implement BPT, is expected to follow the classical marketing
authorization and market placement procedures. The costs
for developing BPT following these frameworks can be as
much as 400–800 million USD [15] and not realistic for
nonprofit actors.
In addition, intellectual property rights (IPRs) that in
general provide owners exclusivities to recoup investment
costs are hardly unavailable (or weak) in the context of BPT
[15]. The reason is that IPRs do not protect natural products
(e.g., natural bacteriophages) or processes covering natural
phenomena (e.g., mechanism of action of BPT based on
the inherent coevolution of bacteria and bacteriophages).
However, given the widespread availability of bacteriophages
and the fact that natural bacteriophages are from a structural
point of view less complex than other biological (protein-
based) products or advanced therapies medicinal products,
the costs to develop BPT could eventually be lower compared
with these latter medicinal products.
Will the overall health benefits of saving thousands
of lives, generated by the introduction of BPT, cross the
option’s threshold (the height of which is determined by the
option’s moral force)? To verify this, we need to compare the
costs of investment in BPT development by pharmaceutical
companies with the unproven potential BPT of, for example,
savings of the lives of 25.000 Europeans each year [28, 30,
38], with the cost associated with bacterial outbreaks caused
by bacterial infections [47], costs to the social security for
hospitalized patients [3], and emotional costs associated with
the disease itself. According to the authors of this paper,
these costs to society by not developing BPT clearly indicate
that the option’s threshold protecting the pharmaceutical
industry’s private interests will be crossed. In our opinion,
pharmaceutical companies hence do have a moral duty to
contribute in one or another way to the development of
BPT.Thinking of phage therapy as a sustainable antibacterial
approach should have the potential of cost reduction for
society that should be considered as a major incentive
for companies to invest in BPT. However, in the current
regulatory climate, the pharmaceutical companies are unable
to do it without adequate incentives or support. Clearly other
stakeholders like the public authorities need to provide the
right incentives by creating feasible regulatory frameworks.
4. Closing the Moral Gap
4.1. Reconciling Private Interests and Social Responsibilities.
According to the authors, previous analysis demonstrates that
arguments can be found to support a moral requirement for
the pharmaceutical industry to promote BPT. It remains to be
seen what specific form this moral requirement will take.The
pharmaceutical industry, due to its specific knowledge and
know-how, will certainly have some role to play in the valida-
tion process of the clinical data relating to BPT (obstacle (1))
and/or in furthering the research concerning the potential
negative coevolutionary consequences of unlimited use of
BFT (obstacle (4)). In addition, it is important to consider
how in the future industrial companies will maintain (keep
on respecting) this moral duty and how these companies can
bemade aware of the importance of creating andmaintaining
high moral standards in the long run. History portrays
similar developments, more specific in the domain of cell
and gene therapy. Several regulatory incentives, specific types
of subsidies and models for public-private partnerships have
contributed to stimulate the industry for investments into
these therapies [48]. More in particular, a specific European
framework covering advanced therapy medicinal product
(Regulation 1394/2007) was created, offering legal incentives
(e.g., scientific advice at reduced costs) to developers of
cell and gene based therapies. Specific calls for research
funding were launched via the FP7 programs of the European
Commission, and large-scale collaborative efforts are in place
between industry and academia, under the umbrella of, for
example, Europe’s Innovative Medicines Initiative (IMI).
4.2. Other Stakeholders’ Responsibilities. Until now we have
solely focused on the pharmaceutical industry as the prin-
cipal bearer of this potential moral requirement to promote
BPT. Obviously, political authorities, much more so than
private companies, have a social responsibility to promote
public health in themost efficient way they can.What ismore,
due to their public nature, public authorities cannot hide
behind cost-based options to protect their “private” interests
as private companies can. As such, since we have shown
that according to the evidence available, the promotion of
flexible (characterized by its locally produced and tailor-
made nature) and sustainable BPT is, compared to other
alternatives, for different particular disease situations, the
best solution to promote overall health benefits, then there is a
publicmoral duty to do so.This particular public requirement
to promote this specific kind of BPT can perhaps best man-
ifest itself by providing an adapted regulatory framework, so
that the full potential of BPT as a locally prepared and tailor-
made therapy can finally be realized.
5. Conclusion
In this paper, we have argued that the current state of affairs
as described in the introduction is morally unacceptable.
BioMed Research International 7
We succeeded in underpinning the desirability for developing
a flexible and sustainable BPT-adapted regulatory framework
with the necessary moral force. The authors are aware that
moral arguments in favour of BPT may equally be identified
(via a similar moral analysis) and apply to other areas of
drug development (e.g., orphan diseases). We argued that the
pharmaceutical industry has a moral duty to invest in BPT
in view of the social responsibility they need to take. But
of equally crucial importance is the role of the competent
public authorities to create the appropriate regulatory and
legal framework to stimulate companies to invest in BPT.
Political representatives and lawmakers have an inevitable,
logical responsibility to support health care and welfare.That
is what they are for. We identified a shared responsibility
making BPT accessible for patients in need. The develop-
ment and production of BPT products in a pharmaceutical
context (clinical trials, production requirements, marketing
authorization procedures...) requires time. Patients in need
have no time. Therefore, lawmakers and regulators need to
design appropriate solutions on a short term to buffer for the
years needed for companies to develop BPT-based medicinal
products. Much more urgent and optimal, regulatory solu-
tions need to be created to allow hospitals to adopt patient-
oriented and tailored BPT in a legal way for treating those
patients that are waiting to be cured.
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